|
RBL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.72473146875518E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.45570280461061E-11 |
| Normal-vs-Stage2 |
5.62419999461383E-08 |
| Normal-vs-Stage3 |
9.34141652919607E-13 |
| Normal-vs-Stage4 |
6.28110008449312E-10 |
| Stage1-vs-Stage2 |
2.915000E-01 |
| Stage1-vs-Stage3 |
2.066100E-02 |
| Stage1-vs-Stage4 |
1.470600E-01 |
| Stage2-vs-Stage3 |
5.630200E-01 |
| Stage2-vs-Stage4 |
7.908000E-01 |
| Stage3-vs-Stage4 |
7.544600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.539391002505E-13 |
| Normal-vs-AfricanAmerican |
5.003000E-04 |
| Normal-vs-Asian |
6.33219999990331E-07 |
| Caucasian-vs-AfricanAmerican |
3.540600E-01 |
| Caucasian-vs-Asian |
5.748600E-01 |
| AfricanAmerican-vs-Asian |
6.638600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.77191594730175E-13 |
| Normal-vs-Female |
9.33542132486309E-12 |
| Male-vs-Female |
2.051600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.57720003723938E-09 |
| Normal-vs-Age(41-60Yrs) |
2.08010275670745E-11 |
| Normal-vs-Age(61-80Yrs) |
3.16602299932356E-12 |
| Normal-vs-Age(81-100Yrs) |
8.154800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.719990E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.697660E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.149600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.359200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.331600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.190400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.065800E-02 |
| Classical-VS-Follicular |
1.256020E-02 |
| Classical-VS-Other |
5.394000E-01 |
| Classical-VS-Normal |
1.2679002292515E-10 |
| Tall-VS-Follicular |
9.910200E-01 |
| Tall-VS-Other |
7.973000E-01 |
| Tall-VS-Normal |
9.02499996957573E-09 |
| Follicular-VS-Other |
8.356400E-01 |
| Follicular-VS-Normal |
2.82480039359712E-10 |
| Other-VS-Normal |
6.177000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.55988588502032E-12 |
| Normal-vs-N1 |
2.78620000404572E-08 |
| N0-vs-N1 |
7.741000E-01 |
|
|
